title: Donor-derived second hematologic malignancies after cord blood transplantation.
abstract: Double umbilical cord blood transplantation (UCBT) with a reduced-intensity conditioning regimen is an effective strategy for adult patients without a matched donor. The risk of second malignancies in these patients has not yet been established, however. In the present study, 98 adults with a hematologic malignancy underwent double UCBT. Seventy patients received a reduced-intensity conditioning regimen of fludarabine 30 mg/m(2)/day for 6 days, melphalan 100 mg/m(2)/day for 1 day, and rabbit antithymocyte globulin 1.5 mg/kg/day for 4 days, and 28 patients received a myeloablative total body radiation-containing conditioning regimen. Sixty-three patients received sirolimus-based graft-versus-host disease (GVHD) prophylaxis, and 35 patients received non-sirolimus-based GVHD prophylaxis. The median patient age was 48 years (range, 19-67 years). Eighteen patients developed a second malignancy at a median of 134 days after transplantation. Sixteen patients had lymphoma, and 2 patients had myelodysplasic syndrome/myeloproliferative disorder (MDS/MPD). Sixteen of these second malignancies (both cases of MDS/MPD and 14 of the lymphomas) were donor-derived; the origins of the others were not determined. GVHD prophylaxis, HLA matching, primary disease, age, total nucleated cell dose, and CD34(+) cell dose were not associated with a higher rate of second malignancy. Second myelogenous malignancies of donor origin occur after double UCBT, suggesting that a search for donor origin should be performed in all patients with suspected relapse.
authors.affiliation: Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Kballen@partners.org
authors.forename: Karen K
authors.initials: KK
authors.lastname: Ballen
authors.forename: Corey
authors.initials: C
authors.lastname: Cutler
authors.forename: Beow Y
authors.initials: BY
authors.lastname: Yeap
authors.forename: Steven L
authors.initials: SL
authors.lastname: McAfee
authors.forename: Bimalangshu R
authors.initials: BR
authors.lastname: Dey
authors.forename: Eyal C
authors.initials: EC
authors.lastname: Attar
authors.forename: Yi-Bin
authors.initials: YB
authors.lastname: Chen
authors.forename: Richard L
authors.initials: RL
authors.lastname: Haspel
authors.forename: Deborah
authors.initials: D
authors.lastname: Liney
authors.forename: John
authors.initials: J
authors.lastname: Koreth
authors.forename: Vincent
authors.initials: V
authors.lastname: Ho
authors.forename: Edwin P
authors.initials: EP
authors.lastname: Alyea
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Soiffer
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Spitzer
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Antin
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects*; D018572:Disease-Free Survival; D005260:Female; D019337:Hematologic Neoplasms / Q000209:etiology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011817:Rabbits; D012189:Retrospective Studies; D014019:Tissue Donors; D019172:Transplantation Conditioning; D055815:Young Adult